Abstract
To the Editor: The presence of circulating tumor cells (CTC) in the peripheral blood of cancer patients has attracted a great deal of attention among investigators. The clinical significance of CTC has probably best been established in breast cancer, where it has been shown that the detection of CTC in metastatic patients correlates with early clinical relapse and patient death [1]. Gene expression profiling of CTC has been extended to other metastatic cancers including colorectal and prostate cancer [2,3]. Recently, a porous barrier density-gradient centrifugation system was developed that allows for enrichment of CTC from peripheral blood [4]. When coupled with the use of specific genes for real-time reverse transcriptase (RT)polymerase chain reaction (PCR), the buoyant density separation approach
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
